Newborn screening helps identify babies who may be at an increased risk for serious, but treatable, conditions in childhood. While the state public health program is the best way to ensure that every baby is tested, the list of conditions on the newborn screening panel varies by state.
Baebies newborn screening services offer ways to address the gap between state programs and available therapies. Our CLIA-certified lab provides services for hospitals, birthing centers, and families.
Newborn Screening for Hospitals
Hospitals can offer screening to the families who give birth in their facilities for conditions that are not universally screened for in U.S. public health newborn screening. Sample collection is done at the hospital or birthing center and sent to Baebies, where screening is performed in our CLIA-certified lab. Through formalized partnerships, Baebies is currently able to offer newborn screening at no cost for Duchenne muscular dystrophy (DMD) in all hospitals and birthing centers.
Baebies partners with CureDuchenne to offer Duchenne muscular dystrophy newborn screening.
CureDuchenne is an advocacy group striving to save this generation of children and young adults with Duchenne muscular dystrophy. A simple blood test checks that newborn’s muscles are healthy and not affected by Duchenne muscular dystrophy. Until Duchenne is added to standard newborn screening, through this partnership, Baebies is able to offer newborn screening at no cost for Duchenne muscular dystrophy at hospitals and birthing centers.
Lab Services Advisory Board
Matthew first trained in next generation sequencing in 2005 at the BC Genome Sciences center where he wrote the first analysis packages for NGS ChIP-seq and RNAseq data. Subsequently he worked under Dr. Richard Gibbs at the Human Genome Sequencing center in Houston, Texas, where he helped launch the first clinical exome sequencing tests. Currently he works at Rady Children’s Institute for Genomic Medicine where his lab focuses on increasing the diagnostic rate by incorporating novel analysis methods of WGS data and close integration of in vivo model systems with the clinic.